Roivant Sciences Ltd. reported an EPS of -$0.29, missing the estimated EPS of -$0.16, indicating a negative earnings surprise of 37.5%.
The company generated $7.57 million in revenue, surpassing the estimated $5.19 million but falling short of the previous year’s $28.93 million.
Despite financial challenges, Roivant maintains a low debt-to-equity ratio of 0.019 and a strong current ratio of 37.91, indicating good short-term liquidity.
Roivant Sciences Ltd., trading as NASDAQ:ROIV, is a biopharmaceutical company focused on developing transformative medicines. The company operates in the competitive biomedical and genetics industry, where it faces rivals like Moderna and BioNTech. Roivant’s recent financial performance has been mixed, with some metrics falling short of expectations while others have exceeded them.
On May 29, 2025, Roivant reported an earnings per share (EPS) of -$0.29, missing the estimated EPS of -$0.16. This represents a negative earnings surprise of 37.5%, as highlighted by Zacks. Despite this, the company showed a slight improvement from the previous year’s loss of $0.23 per share. Over the past four quarters, Roivant has exceeded consensus EPS estimates twice, indicating some volatility in its earnings performance.
In terms of revenue, Roivant generated $7.57 million, surpassing the estimated $5.19 million. However, this figure fell short of the Zacks Consensus Estimate by 88.76% and was significantly lower than the $28.93 million reported in the same quarter the previous year. Despite these challenges, Roivant has managed to exceed consensus revenue estimates twice in the last four quarters, demonstrating some resilience in its revenue generation.
Roivant’s financial ratios reveal a challenging financial position. The company has a negative price-to-earnings (P/E) ratio of -70.03, indicating a lack of profitability. The price-to-sales ratio of 82.65 and enterprise value to sales ratio of 63.27 suggest that investors are paying a high price for each dollar of sales. Additionally, the enterprise value to operating cash flow ratio is -7.96, further highlighting financial difficulties. The earnings yield of -1.43% is another indicator of the company’s current lack of profitability.
Despite these challenges, Roivant maintains a low debt-to-equity ratio of 0.019, indicating minimal reliance on debt financing. The company also boasts a strong current ratio of 37.91, suggesting excellent short-term liquidity. These metrics reflect Roivant’s ability to manage its short-term obligations effectively, even as it navigates financial challenges.
